SCHEMBL13254263

SCHEMBL13254263

CCOC(=O)Cc1ccc(OC2CCN(CC(O)(c3cn(Cc4ccccc4F)c4cc(Br)ccc34)C(F)(F)F)CC2)c(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.34
POLB P06746 2/20 0.34
MAPT P10636 1/20 0.34
HRH2 P25021 3/20 0.34
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
TSHR P16473 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603366 0.94 MAPT (0.36) PDE4BPOLBMAPTHRH2KDM4E
SCHEMBL3597402 0.92 HRH2 (0.36) PDE4BPOLBMAPTHRH2KDM4E
SCHEMBL13254208 0.91 PDE4B (0.33) PDE4BPOLBMAPTHRH2BCHE
SCHEMBL14160158 0.91 GPR6 (0.35) PDE4BPOLBMAPT
SCHEMBL13254252 0.90 PDE4B (0.33) PDE4BPOLBMAPTBCHEACHE
SCHEMBL3598098 0.89 MAPT (0.37) PDE4BPOLBMAPTHRH2BCHE
SCHEMBL3592032 0.88 ALDH1A1 (0.33) PDE4BPOLBKDM4EALDH1A1MEN1
SCHEMBL13254220 0.86 SIGMAR1 (0.32) POLBMAPTHRH2ACHEKDM4E
SCHEMBL13254210 0.86 MAPT (0.32) POLBMAPTHRH2ALDH1A1MEN1
SCHEMBL16327040 0.86 USP14 (0.35) MAPTHRH2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE NR3C1, NR3C2, NR0B1 PDE4B 1999/4885POLB 4635/4885MAPT 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.